Transient rapamycin treatment avoids unwanted host immune responses toward AAV-delivered anti-HIV antibodies. - Fuchs SP; Mondragon PG; Zabizhin R; Tomer S; Wang L; Cook E; Dudley DM; Weisgrau KL; Furlott J; Coonen J; Alexander E; Xie J; et al. (Nature communications, 2025)